Figure 5

Sunitinib treatment results in tumour vessel regression and reduced RT2 tumour growth. (A) Treatment and imaging protocol. (B) Image panels showing representative RT2 tumours exposed to sham and Sunitinib treatment at indicated time-points. Tumour cells were visualized by scattered light (grey scale), and tumour vessels by Texas Red-70 kDa dextran administered to the circulation (Texas Red) (red). Bottom row represents merged images. Scale bars represents 50 μm. (C) Quantification of indicated tumour vascular parameters showing fold changes after one week (W3/W2) and two weeks (W4/W2) of control and Sunitinib treatment. (D) Graphs showing the growth of tumours during the entire study protocol. (E) Fold changes in tumour volume after two weeks of control and Sunitinib treatment. (control = 9, Sunitinib = 12). Statistics: (C) Mann-Whitney-Wilcoxon Test, median ± SD, (E) Student’s t-test mean ± SD; *P < 0.05, **P < 0.01,***P < 0.001.